Review
Biotechnology & Applied Microbiology
Andrzej Jachowski, Mikolaj Marcinkowski, Jakub Szydlowski, Oskar Grabarczyk, Zuzanna Nogaj, Laz Marcin, Andrzej Plawski, Pawel Piotr Jagodzinski, Bartosz Kazimierz Slowikowski
Summary: Lung cancer, especially nonsmall cell lung cancer (NSCLC), is a highly prevalent and deadly disease worldwide. The treatment for NSCLC has evolved from traditional approaches to more personalized and minimally invasive methods, improving efficacy and reducing side effects. This review discusses established modern approaches such as immunotherapy and targeted therapy, as well as experimental methods like CRISPR and nanoparticles, which offer promising outcomes and faster recovery time for patients.
JOURNAL OF APPLIED GENETICS
(2023)
Article
Medicine, General & Internal
Ibrahim Azar, Omid Yazdanpanah, Hyejeong Jang, Adam Austin, Seongho Kim, Jie Chi, Samer Alkassis, Biplab K. Saha, Amit Chopra, Kristoffer Neu, Syed Mehdi, Hirva Mamdani
Summary: There is no significant difference in survival outcomes between cisplatin and carboplatin for the treatment of both limited-stage and extensive-stage small cell lung cancer (SCLC). The favorable toxicity profile of carboplatin and comparable overall survival support its use in clinical practice for both types of SCLC and allow for combination with novel treatment strategies in clinical trials.
Article
Respiratory System
Florian Eichhorn, Hauke Winter
Summary: Patients with oligometastatic lung cancer, defined as having limited metastatic disease, may have better prognosis when treated with local ablative therapy for all lesions. In such cases, surgery and radiotherapy play a dominant role in the treatment course, offering a potentially curative local therapy in combination with systemic treatment based on interdisciplinary decisions.
EUROPEAN RESPIRATORY REVIEW
(2021)
Review
Pharmacology & Pharmacy
Zi-Xian Liao, Ivan M. Kempson, Chia-Chen Hsieh, S-Ja Tseng, Pan-Chyr Yang
Summary: The presence of lactate and its relationship with drug resistance and genetic mutations in NSCLC highlights the potential for improving therapeutic outcomes by enzymatically lowering lactate levels. Targeting lactate may promote an oncolytic immune microenvironment within the tumor, offering a promising approach for enhancing NSCLC treatment efficacy.
DRUG DISCOVERY TODAY
(2021)
Review
Medical Laboratory Technology
Lea Sinoquet, William Jacot, Xavier Quantin, Catherine Alix-Panabieres
Summary: This study discusses the application of immune checkpoint inhibitors in the treatment of metastatic nonsmall cell lung cancer and focuses on the evaluation of blood biomarkers such as circulating cell-free DNA, circulating tumor DNA, blood tumor mutational burden, and circulating tumor cells. Monitoring these biomarkers during immunotherapy may assist clinicians in making therapeutic decisions.
CLINICAL CHEMISTRY
(2023)
Article
Oncology
Xiaodong Gu, Zhiyong Shi, Lan Shao, Yuxin Zhang, Yiping Zhang, Zhengbo Song, Wenxian Wang, Guangyuan Lou
Summary: For patients with advanced NS-NSCLC, ICIs monotherapy or in combination with pemetrexed can be used as maintenance therapy after first-line treatment. The choice between the two options should be based on the patient's PD-L1 expression level. There was no significant difference in median progression-free survival and 2-year survival rates between the two groups, but the incidence of fatigue was higher in the ICIs plus pemetrexed group.
Article
Oncology
Brittney Chau, Philip H. G. Ituarte, Ashwin Shinde, Richard Li, Jessica Vazquez, Scott Glaser, Erminia Massarelli, Ravi Salgia, Loretta Erhunmwunsee, Kimlin Ashing, Arya Amini
Summary: The study found that foreign-born NSCLC patients in California have a lower risk of mortality compared to native-born patients after adjusting for treatments received and socioeconomic factors.
Review
Oncology
Kit Yee Wong, Alvin Ho-Kwan Cheung, Bonan Chen, Wai Nok Chan, Jun Yu, Kwok Wai Lo, Wei Kang, Ka Fai To
Summary: Lung cancer is a common and deadly disease, with the tumor microenvironment playing a crucial role. Cancer-associated fibroblasts (CAFs) have gained attention in the study of nonsmall cell lung carcinoma (NSCLC), as their heterogeneity and functions are closely associated with tumor development.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Respiratory System
Rudolf M. Huber, Diego Kauffmann-Guerrero, Hans Hoffmann, Michael Flentje
Summary: Recent developments in the treatment of locally advanced nonsmall cell lung cancer have focused on integrating immunotherapy with radiotherapy, chemotherapy, and adjuvant targeted therapy. The importance of consolidation therapy, pathological evaluation, and investigation of immunological features and driver mutations in improving management and prognosis has been emphasized.
EUROPEAN RESPIRATORY REVIEW
(2021)
Article
Chemistry, Multidisciplinary
Elham Hatami, Prashanth K. B. Nagesh, Mohammed Sikander, Anupam Dhasmana, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu
Summary: The study demonstrates that Tannic acid (TA) has antiproliferative and antiangiogenic effects against nonsmall-cell lung cancer (NSCLC).
Article
Critical Care Medicine
Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, QiMing Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, LiPing Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, XiaoRong Dong, Tao Zhang, Wei Shi, Jianjun Zou
Summary: The study showed a statistically significant and clinically meaningful improvement in progression-free survival with camrelizumab plus chemotherapy compared to chemotherapy alone, making it a promising first-line treatment option for Chinese patients with advanced non-squamous NSCLC without EGFR and ALK alterations, with further long-term outcomes and confirmatory testing still ongoing.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Oncology
Edward B. Garon, Patrick Peterson, Maria Teresa Rizzo, Jong Seok Kim
Summary: This study pooled and analyzed data from randomized studies to compare the overall survival and safety of pemetrexed-only maintenance versus pemetrexed +/- anti-VEGF maintenance in patients with advanced nonsquamous non-small-cell lung cancer. The results showed no significant difference in overall survival between the two maintenance therapies and both were well-tolerated.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Aria Shokoohi, Zamzam Al-Hashami, Sara Moore, Alexandra Pender, Selina K. Wong, Ying Wang, Bonnie Leung, Jonn Wu, Cheryl Ho
Summary: The evolution of diagnosis and treatment for advanced NSCLC, including targeted therapy and immune checkpoint inhibitors, has significantly improved overall survival. With the introduction of targeted therapy and immunotherapy, there was a notable increase in survival in each successive time cohort, reflecting advancements in treatment options.
Article
Oncology
Masahiro Shinoda, Masaharu Shinkai, Yu Hara, Kouji Tomaru, Saki Manabe, Syuji Murakami, Haruhiro Saito, Nobuaki Kobayashi, Naoki Miyazawa, Masanori Nishikawa, Takeshi Kaneko
Summary: Carboplatin plus pemetrexed followed by maintenance pemetrexed for elderly patients with previously untreated advanced non-squamous non-small cell lung cancer is effective and well-tolerated, with a 1-year survival rate of 73% and manageable toxicities.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Corey J. Langer, Ajeet Gajra, Cesare Gridelli, Kartik Konduri, Daniel Morgensztern, David Spigel, Denis Talbot, Michael Thomas, Jared Weiss, Richard Pilot, Rafia Bhore, Marianne Wolfsteiner, Teng Jin Ong, Mark Socinski
Summary: Despite the underrepresentation of certain patient populations in clinical trials for advanced NSCLC, a pooled analysis of elderly patients and those with renal impairment, diabetes, or poor performance status showed varying but promising outcomes, supporting the use of nab-paclitaxel-based regimens in these historically understudied and vulnerable populations.
FRONTIERS IN ONCOLOGY
(2021)